Patents by Inventor Jurgen M. Lehmann

Jurgen M. Lehmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of FXR ligands
    Patent number: 6984650
    Abstract: The present invention includes nuclear receptor heterodimer and nuclear receptor-coactivator peptide assays for identifying ligands for nuclear receptors, utilizing scintillation proximity and fluorescence resonance energy transfer (FRET), and methods of using identified ligands.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: January 10, 2006
    Assignee: Smithkline Beecham Corporation
    Inventors: Curt Dale Haffner, Patrick Reed Maloney, Timothy Mark Willson, Steven Gerard Blanchard, Steven A. Kliewer, Jurgen M. Lehmann, Derek James Parks, Julie Beth Stimmel
  • Car modulators: screening and treatment of hypercholesterolemia
    Publication number: 20020152479
    Abstract: This invention provides methods that are useful for identifying therapeutic agents for the treatment of a CAR-mediated disorder or condition. The methods include determining whether the candidate therapeutic agent can: interact directly with CAR, modulate CAR-mediated gene expression, decrease CAR antagonist elevation of a cholesterol indicator in a mammal, or decrease a cholesterol level indicator in a mammal with a defective CAR. Also provided are CAR agonists.
    Type: Application
    Filed: January 12, 2001
    Publication date: October 17, 2002
    Inventors: Jurgen M. Lehmann, Andrew Kwan-Nan Shiau
  • Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
    Patent number: 5994554
    Abstract: The present invention provides radiolabeled 5-{4-[2-(Methyl-pyridine-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dion e. In another aspect, the present invention provides a method for determining whether a compound does or does not interact directly with PPAR-gamma, comprising the step of specifically binding a radiolabeled compound of this invention to the ligand binding domain of PPAR-gamma.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: November 30, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Steven Anthony Kliewer, Jurgen M. Lehmann, Timothy M. Willson
  • Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
    Patent number: 5902726
    Abstract: The present invention provides activator compounds, including agonists, to the peroxisome proliferator-activated receptor gamma. Particular PPAR.gamma. activators are set forth, as are a pharmaceutical composition for treating diabetes, non-insulin-dependent diabetes mellitus, cardiovascular disorders, and methods for such treatment.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: May 11, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Steven Anthony Kliewer, Jurgen M. Lehmann, Timothy M. Willson
  • Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
    Patent number: 5837725
    Abstract: Bridged bicyclic aromatic compounds are provided having the structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n are as defined herein. The novel compounds are useful for modulating gene expression of retinoic acid receptors, vitamin D receptors and thyroid receptors. Pharmaceutical compositions and methods for modulating gene expression are provided as well.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: November 17, 1998
    Assignees: SRI International, La Jolla Cancer Research Foundation
    Inventors: Marcia I. Dawson, James F. Cameron, Peter D. Hobbs, Ling Jong, Magnus Pfahl, Xiao-kun Zhang, Jurgen M. Lehmann
  • RXR homodimer formation
    Patent number: 5824484
    Abstract: The invention provides a method of screening a substance for the ability to effect the formation of a retinoid X receptor homodimer comprising combining the substance and a solution containing retinoid X receptors and determining the presence of homodimer formation. Also provided is a method of screening a substance for an effect on a retinoid X receptor homodimer's ability to bind DNA comprising combining the substance with the homodimer and determining the effect of the compound on the homodimer's ability to bind DNA. A method of inhibiting an activity of a retinoid X receptor heterodimer comprising increasing the formation of a retinoid X receptor homodimer, thereby preventing the retinoid X receptor from forming a heterodimer and preventing the resulting heterodimer activity is also provided. A method of inhibiting an activity of a retinoid X receptor homodimer is also provided.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: October 20, 1998
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Magnus Pfahl, Xiao-kun Zhang, Jurgen M. Lehmann, Marcia I. Dawson, James F. Cameron, Peter D. Hobbs, Ling Jong
  • Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
    Patent number: 5466861
    Abstract: Bridged bicyclic aromatic compounds are provided having the structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n are as defined herein. The novel compounds are useful for modulating gene expression of retinoic acid receptors, vitamin D receptors and thyroid receptors. Pharmaceutical compositions and methods for modulating gene expression are provided as well.
    Type: Grant
    Filed: November 25, 1992
    Date of Patent: November 14, 1995
    Assignees: SRI International, La Jolla Cancer Research Foundation
    Inventors: Marcia L. Dawson, James F. Cameron, Peter D. Hobbs, Ling Jong, Magnus Pfahl, Xiao-kun Zhang, Jurgen M. Lehmann